Allogene Therapeutics, Inc. (ALLO) financial statements and ratios from SEC XBRL: revenue $0.00 (TTM), revenue growth -100.0% YoY. Income statement, balance sheet, cash flow, and valuation. First-party data.
| Revenue (TTM) | $0.00 |
| Revenue Growth (YoY) | -100.0% |
| EPS Growth (YoY) | -34.1% |
| FCF Growth (YoY) | -25.6% |
| Price / Book | 1.65 |
| Price / Sales | 155.47 |
| FCF Yield | -26.7% |
| Altman Z-Score | -5.30 (distress) |
| Sector P/E (Healthcare) | 21.6 |
ALLO overview · ALLO earnings · ALLO KPIs · ALLO investor relations · ALLO ownership · ALLO peers · ALLO filings
Data sourced from U.S. SEC EDGAR XBRL filings. Not personalized investment advice.